Merck Gains FDA Approval for New Cholesterol Drug, Expands European Operations

Thursday, July 16, 2026·Consolidated from 3 sources

Merck has received FDA approval for LIPFENDRA, a new once-daily oral pill designed to significantly lower LDL cholesterol in adults. This development follows an announcement regarding the company's expansion of its testing capabilities in Europe with a new facility in Darmstadt, Germany. The new drug offers a novel treatment option for hypercholesterolemia patients.

Merck & Co. has achieved a significant regulatory milestone with the U.S. Food and Drug Administration's approval of its new cholesterol-lowering medication, LIPFENDRA (enlicitide). Coverage today notes that LIPFENDRA is the first and only oral PCSK9 inhibitor approved for daily use, offering adults with hypercholesterolemia a new way to reduce their LDL cholesterol levels.

The drug's once-daily oral formulation is highlighted as a key advancement, potentially improving patient adherence and convenience compared to existing treatments. The approval marks Merck's continued commitment to developing innovative therapies for cardiovascular health, a critical area with significant unmet medical needs.

In parallel with this U.S. regulatory success, Merck also announced the opening of its new BioReliance testing facility in Darmstadt, Germany. This expansion is aimed at bolstering the company's drug product release capabilities within Europe. The facility is expected to enhance Merck's ability to serve the European market by providing essential testing services closer to its customer base.

The dual developments in drug approval and operational expansion underscore Merck's strategic focus on both product innovation and global reach. The stock saw a positive reaction in early trading following the news of the FDA approval, reflecting investor confidence in the company's pipeline and market position.

Sources